USA-based Biopure has appointed Dechra Veterinary Products as exclusive distributor for Oxyglobin solution [hemoglobin glutamer-200 (bovine)], in the USA. The agent is the only US-approved treatment for canine anemia, a potentially life-threatening condition.
Under the terms of the deal, Dechra will market Oxyglobin in 60mL single dose and 125mL single dose infusion bags, and Biopure will continue to manufacture the product.
Biopure develops, manufactures and markets oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. In humans, Hemopure is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze